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Introduction {#sec1}
============

Three coronaviruses have crossed the species barrier to cause deadly pneumonia in humans since the beginning of the 21^st^ century: severe acute respiratory syndrome coronavirus (SARS-CoV) ([@bib13], [@bib34]), Middle-East respiratory syndrome coronavirus ([@bib94]) (MERS-CoV), and SARS-CoV-2 ([@bib27], [@bib97]). SARS-CoV emerged in the Guangdong province of China in 2002 and spread to five continents through air travel routes, infecting 8,098 people and causing 774 deaths. In 2012, MERS-CoV emerged in the Arabian Peninsula, where it remains a major public health concern, and was exported to 27 countries, infecting a total of ∼2,494 individuals and claiming 858 lives. A previously unknown coronavirus, named SARS-CoV-2, was discovered in December 2019 in Wuhan, Hubei province of China and was sequenced and isolated by January 2020 ([@bib96], [@bib97]). SARS-CoV-2 is associated with an ongoing outbreak of atypical pneumonia (Covid-2019) that has affected over 90,000 people and killed more than 3,000 of those affected in \>60 countries as of March 3, 2020. On January 30, 2020, the World Health Organization declared the SARS-CoV-2 epidemic a public health emergency of international concern.

MERS-CoV was suggested to originate from bats, but the reservoir host fueling spillover to humans is unequivocally dromedary camels ([@bib23], [@bib48]). Both SARS-CoV and SARS-CoV-2 are closely related and originated in bats, who most likely serve as reservoir host for these two viruses ([@bib17], [@bib26], [@bib40], [@bib91], [@bib96]). Whereas palm civets and racoon dogs have been recognized as intermediate hosts for zoonotic transmission of SARS-CoV between bats and humans ([@bib21], [@bib30], [@bib82]), the SARS-CoV-2 intermediate host remains unknown. The recurrent spillovers of coronaviruses in humans along with detection of numerous coronaviruses in bats, including many SARS-related coronaviruses (SARSr-CoVs), suggest that future zoonotic transmission events may continue ([@bib2], [@bib17], [@bib26], [@bib40], [@bib49], [@bib50], [@bib91], [@bib96]). In addition to the highly pathogenic zoonotic pathogens SARS-CoV, MERS-CoV, and SARS-CoV-2, all belonging to the β-coronavirus genus, four low-pathogenicity coronaviruses are endemic in humans: HCoV-OC43, HCoV-HKU1, HCoV-NL63, and HCoV-229E. To date, no therapeutics or vaccines are approved against any human-infecting coronaviruses.

Coronavirus entry into host cells is mediated by the transmembrane spike (S) glycoprotein that forms homotrimers protruding from the viral surface ([@bib72]). S comprises two functional subunits responsible for binding to the host cell receptor (S~1~ subunit) and fusion of the viral and cellular membranes (S~2~ subunit). For many CoVs, S is cleaved at the boundary between the S~1~ and S~2~ subunits, which remain non-covalently bound in the prefusion conformation ([@bib5], [@bib6], [@bib9], [@bib31], [@bib51], [@bib52], [@bib56], [@bib76]). The distal S~1~ subunit comprises the receptor-binding domain(s) and contributes to stabilization of the prefusion state of the membrane-anchored S~2~ subunit that contains the fusion machinery ([@bib22], [@bib31], [@bib55], [@bib66], [@bib76], [@bib79], [@bib93]). For all CoVs, S is further cleaved by host proteases at the so-called S~2~′ site located immediately upstream of the fusion peptide ([@bib46], [@bib52]). This cleavage has been proposed to activate the protein for membrane fusion via extensive irreversible conformational changes ([@bib5], [@bib24], [@bib51], [@bib52], [@bib56], [@bib79]). As a result, coronavirus entry into susceptible cells is a complex process that requires the concerted action of receptor-binding and proteolytic processing of the S protein to promote virus-cell fusion.

Different coronaviruses use distinct domains within the S~1~ subunit to recognize a variety of attachment and entry receptors, depending on the viral species. Endemic human coronaviruses OC43 and HKU1 attach via their S domain A (S^A^) to 5-N-acetyl-9-*O*-acetyl-sialosides found on glycoproteins and glycolipids at the host cell surface to enable entry into susceptible cells ([@bib28], [@bib73], [@bib75]). MERS-CoV S, however, uses domain A to recognize non-acetylated sialoside attachment receptors ([@bib42], [@bib57]), which likely promote subsequent binding of domain B (S^B^) to the entry receptor, dipeptidyl-peptidase 4 ([@bib45], [@bib59]). SARS-CoV and several SARS-related coronaviruses (SARSr-CoV) interact directly with angiotensin-converting enzyme 2 (ACE2) via S^B^ to enter target cells ([@bib17], [@bib32], [@bib39], [@bib37], [@bib66], [@bib91]).

As the coronavirus S glycoprotein is surface-exposed and mediates entry into host cells, it is the main target of neutralizing antibodies (Abs) upon infection and the focus of therapeutic and vaccine design. S trimers are extensively decorated with N-linked glycans that are important for proper folding ([@bib63]) and for modulating accessibility to host proteases and neutralizing Abs ([@bib77], [@bib80], [@bib89], [@bib92]). We previously characterized potent human-neutralizing Abs from rare memory B cells of individuals infected with SARS-CoV ([@bib74]) or MERS-CoV ([@bib12]) in complex with SARS-CoV S and MERS-CoV S to provide molecular-level information of the mechanism of competitive inhibition of S^B^ attachment to the host receptor ([@bib80]). The S230 anti-SARS-CoV Ab also acted by functionally mimicking receptor attachment and promoting S fusogenic conformational rearrangements through a ratcheting mechanism that elucidated the unique nature of the coronavirus membrane fusion activation ([@bib80]).

We report here that ACE2 could mediate SARS-CoV-2 S-mediated entry into cells, establishing it as a functional receptor for this newly emerged coronavirus. The SARS-CoV-2 S^B^ engages human ACE2 (hACE2) with comparable affinity to SARS-CoV S^B^ from viral isolates associated with the 2002--2003 epidemic (i.e., binding with high affinity to hACE2). Tight binding to hACE2 could partially explain the efficient transmission of SARS-CoV-2 in humans, as was the case for SARS-CoV. We identified the presence of an unexpected furin cleavage site at the S~1~/S~2~ boundary of SARS-CoV-2 S, which is cleaved during biosynthesis---a novel feature setting this virus apart from SARS-CoV and SARSr-CoVs. Abrogation of this cleavage motif moderately affected SARS-CoV-2 S-mediated entry into VeroE6 or BHK cells but may contribute to expand the tropism of this virus, as reported for several highly pathogenic avian influenza viruses and pathogenic Newcastle disease virus ([@bib33], [@bib67]). We determined cryoelectron microscopy (cryo-EM) structures of the SARS-CoV-2 S ectodomain trimer and reveal that it adopts multiple S^B^ conformations that are reminiscent of previous reports on both SARS-CoV S and MERS-CoV S. Finally, we show that SARS-CoV S mouse polyclonal sera potently inhibited entry into target cells of SARS-CoV-2 S pseudotyped viruses. Collectively, these results pave the way for designing vaccines eliciting broad protection against SARS-CoV-2, SARS-CoV, and SARSr-CoV.

Results {#sec2}
=======

ACE2 Is an Entry Receptor for SARS-CoV-2 {#sec2.1}
----------------------------------------

The SARS-CoV-2 S glycoprotein shares 76% amino acid sequence identity with the SARS-CoV S Urbani and 80% identity with bat SARSr-CoV ZXC21 S and ZC45 S glycoprotein. The latter two SARSr-CoV sequences were identified from *Rinolophus sinicus* (Chinese horseshoe bats), the species from which SARSr-CoV WIV-1 and WIV-16 were isolated ([@bib17], [@bib91]). Furthermore, [@bib96] recently reported that SARS-CoV-2 is most closely related to the bat SARSr-CoV RaTG13, with which it forms a distinct lineage from other SARSr-CoVs, and that their S glycoproteins share 97% amino acid sequence identity. SARS-CoV recognizes its entry receptor hACE2 at the surface of type II pneumocytes using S^B^, which shares ∼75% overall amino acid sequence identity with SARS-CoV-2 S^B^ and 50% identity within their receptor-binding motifs (RBMs) ([@bib39], [@bib37], [@bib41], [@bib81]). Previous studies also showed that the host proteases cathepsin L and TMPRSS2 prime SARS-CoV S for membrane fusion through cleavage at the S~1~/S~2~ and at the S~2~′ sites ([@bib5], [@bib7], [@bib18], [@bib47], [@bib52], [@bib65]).

We set out to investigate the functional determinants of S-mediated entry into target cells using a murine leukemia virus (MLV) pseudotyping system ([@bib53]). To assess the ability of SARS-CoV-2 S to promote entry into target cells, we first compared transduction of SARS-CoV-2 S-MLV and SARS-CoV S-MLV into VeroE6 cells, that are known to express ACE2 and support SARS-CoV replication ([@bib13], [@bib34]). Both pseudoviruses entered cells equally well ([Figure 1](#fig1){ref-type="fig"} A), suggesting that SARS-CoV-2 S-MLV could use African green monkey ACE2 as entry receptor. To confirm these results, we evaluated entry into BHK cells and observed that transient transfection with hACE2 rendered them susceptible to transduction with SARS-CoV-2 S-MLV ([Figure 1](#fig1){ref-type="fig"}B). These results demonstrate hACE2 is a functional receptor for SARS-CoV-2, in agreement with recently reported findings ([@bib25], [@bib35], [@bib96]).Figure 1ACE2 Is a Functional Receptor for SARS-CoV-2 S(A) Entry of MLV pseudotyped with SARS-CoV-2 S, SARS-CoV S and SARS-CoV-2 S~fur/mut~ in VeroE6 cells. Data are represented as mean ± standard deviation of technical triplicates.(B) Entry of MLV pseudotyped with SARS-CoV-2 S or SARS-CoV-2 S~fur/mut~ in BHK cells transiently transfected with hACE2. The experiments were carried out with two independent pseudovirus preparations and a representative experiment is shown. Data are represented as mean ± standard deviation of technical triplicates.(C) Sequence alignment of SARS-CoV-2 S with multiple related SARS-CoV and SARSr-CoV S glycoproteins reveals the introduction of an S~1~/S~2~ furin cleavage site in this novel coronavirus. Identical and similar positions are respectively shown with white or red font. The four amino acid residue insertion at SARS-CoV-2 S positions 681-684 is indicated with periods. The entire sequence alignment is presented in [Data S1](#mmc2){ref-type="supplementary-material"}.(D) Western blot analysis of SARS-CoV S-MLV, SARS-CoV-2 S-MLV, and SARS-CoV-2 S~fur/mut~-MLV pseudovirions. See also [Data S1](#mmc2){ref-type="supplementary-material"}.

Sequence analysis of SARS-CoV-2 S reveals the presence of a four amino acid residue insertion at the boundary between the S~1~ and S~2~ subunits compared with SARS-CoV S and SARSr-CoV S ([Figure 1](#fig1){ref-type="fig"}C). This results in the introduction of a furin cleavage site, a feature conserved among the 144 SARS-CoV-2 isolates sequenced to date but not in the closely related RaTG13 S ([@bib96]). Using western blot analysis, we observed that SARS-CoV-2 S was virtually entirely processed at the S~1~/S~2~ site during biosynthesis in HEK293T cells, presumably by furin in the Golgi compartment ([Figure 1](#fig1){ref-type="fig"}D). This observation contrasts with SARS-CoV S, which was incorporated into pseudovirions largely uncleaved ([Figure 1](#fig1){ref-type="fig"}D). To study the influence on pseudovirus entry of the SARS-CoV-2 S~1~/S~2~ furin cleavage site, we designed an S mutant lacking the four amino acid residue insertion and the furin cleavage site by mutating Q~677~T**NSPRR**AR↓SV~687~ (wild-type SARS-CoV-2 S) to Q~677~T**IL**R↓SV~683~ (SARS-CoV-2 S~fur/mut~). SARS-CoV-2 S~fur/mut~ preserves only the conserved arginine residue at position 685 of wild-type SARS-CoV-2 S, thereby mimicking the S~1~/S~2~ cleavage site of the related SARSr-CoV S CZX21 ([Figure 1](#fig1){ref-type="fig"}D). SARS-CoV-2 S~fur/mut~ is therefore expected to undergo processing at the S~1~/S~2~ site upon encountering a target cell, similar to SARS-CoV S and SARSr-CoV S, i.e., via TMPRSS2 and/or cathepsin L ([@bib5], [@bib7], [@bib18], [@bib47], [@bib52], [@bib65]). As expected, SARS-CoV-2 S~fur/mut~-MLV harbored uncleaved S upon budding ([Figure 1](#fig1){ref-type="fig"}D). The observed transduction efficiency of VeroE6 cells was higher for SARS-CoV-2 S~fur/mut~-MLV than for SARS-CoV-2 S-MLV ([Figure 1](#fig1){ref-type="fig"}A), whereas the opposite trend was observed for transduction of hACE2-expressing BHK cells ([Figure 1](#fig1){ref-type="fig"}B). These results suggest that S~1~/S~2~ cleavage during S biosynthesis was not necessary for S-mediated entry in the conditions of our experiments ([Figures 1](#fig1){ref-type="fig"}C and 1D). We speculate that the detection of a polybasic cleavage site in the fusion glycoprotein of SARS-CoV-2 could putatively expand its tropism and/or enhance its transmissibility, compared with SARS-CoV and SARSr-CoV isolates, due to the near-ubiquitous distribution of furin-like proteases and their reported effects on other viruses ([@bib33], [@bib52], [@bib67]).

SARS-CoV-2 Recognizes hACE2 with Comparable Affinity to SARS-CoV {#sec2.2}
----------------------------------------------------------------

The binding affinity of SARS-CoV for hACE2 correlates with the overall rate of viral replication in distinct species as well as with transmissibility and disease severity ([@bib21], [@bib38], [@bib41], [@bib81]). Indeed, specific S^B^ mutations enabled efficient binding to hACE2 of SARS-CoV isolates from the three phases of the 2002--2003 epidemic, which were associated with marked disease severity ([@bib11], [@bib30], [@bib41], [@bib68]). In contrast, SARS-CoV isolates detected during the brief 2003--2004 re-emergence interacted more weakly with hACE2 and had low pathogenicity and transmissibility ([@bib11], [@bib30], [@bib41]).

To understand the contribution of receptor interaction to the infectivity of SARS-CoV-2, we characterized engagement of hACE2 by SARS-CoV-2 S^B^ and SARS-CoV S^B^ side-by-side. We used biolayer interferometry to study binding kinetics and affinity of the purified hACE2 ectodomain to SARS-CoV-2 S^B^ and SARS-CoV S^B^ immobilized at the surface of biosensors. We found that hACE2 bound to SARS-CoV-2 S^B^ and SARS-CoV S^B^ with respective equilibrium dissociation constants of 1.2 nM ([Figure 2](#fig2){ref-type="fig"} A) and 5.0 nM ([Figure 2](#fig2){ref-type="fig"}B), and comparable kinetic rate constants, although the off-rate, were slightly higher for SARS-CoV S^B^ ([Table 1](#tbl1){ref-type="table"} ). The affinity determined here for SARS-CoV S^B^ binding to hACE2 is in line with prior studies and the tighter apparent interactions formed by SARS-CoV S^B^ compared with the SARS-CoV S~1~ subunit or the SARS-CoV S trimer ([@bib32], [@bib41], [@bib68], [@bib80], [@bib85]). Previous structural work identified 14 positions that are key for binding of SARS-CoV S^B^ to hACE2: T402, R426, Y436, Y440, Y442, L472, N473, Y475, N479, Y484, T486, T487, G488, and Y491 ([@bib39]). Analysis of the 144 SARS-CoV-2 genome sequences available from the Global Initiative on Sharing All Influenza Data (GISAID) ([@bib14]) shows that 8 out of these 14 positions are strictly conserved in SARS-CoV-2 S^B^, whereas the other 6 positions are (semi)conservatively substituted: R426~SARS-CoV~N439~SARS-CoV-2~, Y442~SARS-CoV~L455~SARS-CoV-2~, L472~SARS-CoV~F486~SARS-CoV-2~, N479~SARS-CoV~Q493~SARS-CoV-2~, Y484~SARS-CoV~Q498~SARS-CoV-2~, and T487~SARS-CoV~N501~SARS-CoV-2~ ([Figure 2](#fig2){ref-type="fig"}C). The conservation of many key contact residues could explain the similar binding affinities of SARS-CoV-2 S^B^ and SARS-CoV S^B^ for hACE2. No mutations of residues predicted to contact hACE2 have been observed among SARS-CoV-2 S sequences available to date. However, we note that SARSr-CoV ZXC21 and ZC45, which harbor the most closely related S sequences after SARSr-CoV RaTG13, have a deletion in the RBD that could affect binding to hACE2 (between SARS-CoV-2 S residues 473--486 ) ([Data S1](#mmc2){ref-type="supplementary-material"}). Collectively, these results suggest that SARS-CoV-2 is at least as well adapted to the hACE2 ortholog as the 2002--2003 epidemic strains of SARS-CoV, which could explain the efficient transduction efficiency mediated by their respective S glycoproteins ([Figures 1](#fig1){ref-type="fig"}A and 1B) and the current rapid SARS-CoV-2 transmission in humans.Figure 2SARS-CoV-2 S Recognizes hACE2 with Comparable Affinity to SARS-CoV S(A and B) Biolayer interferometry binding analysis of the hACE2 ectodomain to immobilized SARS-CoV-2 S^B^ (A) or SARS-CoV S^B^ (B). The experiments were repeated with different protein preparations and one representative set of curves is shown. Dotted lines correspond to a global fit of the data using a 1:1 binding model.(C) Sequence alignment of SARS-CoV-2 S^B^ and SARS-CoV S^B^ Urbani (late phase of the 2002--2003 SARS-CoV epidemic). Identical and similar positions are respectively shown with white or red font. The single amino acid insertion at position 483 of the SARS-CoV-2 S^B^ is indicated with a period at the corresponding SARS-CoV S^B^ position. The 14 residues that are key for binding of SARS-CoV S^B^ to hACE2 are labeled with a star. See also [Data S1](#mmc2){ref-type="supplementary-material"}.Table 1Kinetic Analysis of hACE2 Binding to SARS-CoV-2 S^B^ and SARS-CoV S^B^ by Biolayer InterferometrySARS-CoV-2 S^B^SARS-CoV S^B^K~D~ (nM)1.2 ± 0.15.0 ± 0.1k~on~ (M^−1^.s^−1^)1.4 × 10^5^ (2.3 ± 1.4 × 10^5^)1.4 × 10^5^ (1.7 ± 0.7 × 10^5^)k~off~ (s^−1^)1.6 × 10^−4^ (1.7 ± 0.8 × 10^−4^)7.1x 10^−4^ (8.7 ± 5.1 × 10^−4^)[^3]

Architecture of the SARS-CoV-2 S Glycoprotein Trimer {#sec2.3}
----------------------------------------------------

To enable single-particle cryo-EM study of the SARS-CoV-2 S glycoprotein, we designed a prefusion stabilized ectodomain trimer construct with an abrogated furin S~1~/S~2~ cleavage site ([@bib73], [@bib78], [@bib76], [@bib80]), two consecutive proline stabilizing mutations ([@bib32], [@bib55]), and a C-terminal foldon trimerization domain ([@bib54]). Three-dimensional (3D) classification of the cryo-EM data revealed the presence of multiple conformational states of SARS-CoV-2 S corresponding to distinct organization of the S^B^ domains within the S~1~ apex. Approximately half of the particle images selected correspond to trimers harboring a single S^B^ domain opened whereas the remaining half was accounted for by closed trimers with the three S^B^ domains closed. A recently determined SARS-CoV-2 S structure also detected trimers with a single S^B^ domain opened but none entirely closed ([@bib87]). The observed conformational variability of S^B^ domains is reminiscent of observations made with SARS-CoV S and MERS-CoV S trimers, although we did not detect trimers with two S^B^ domains open and the distribution of particles across the S conformational landscape varies among studies ([@bib22], [@bib32], [@bib55], [@bib66], [@bib80], [@bib93]).

We determined a reconstruction of the closed SARS-CoV-2 S ectodomain trimer at 2.8 Å resolution (applying 3-fold symmetry) and an asymmetric reconstruction of the trimer with a single S^B^ domain opened at 3.2 Å resolution ([Figures 3](#fig3){ref-type="fig"} A--3H and [S1](#figs1){ref-type="fig"} ; [Table S1](#mmc1){ref-type="supplementary-material"}). The S~2~ fusion machinery is the best resolved part of the map, whereas the S^A^ and S^B^ domains are less well resolved, presumably because of conformational heterogeneity. The atomic model comprises residues 27-1147, with internal breaks corresponding to flexible regions (including part of the RBM), and lacks the C-terminal most segment (including the heptad repeat 2) that is not visible in the map, as is the case for all S structures determined to date. Overall, the SARS-CoV-2 S ectodomain is a 160-Å-long trimer with a triangular cross-section, resembling the closely related SARS-CoV S structure ([Figures S2](#figs2){ref-type="fig"} A--S2F) ([@bib22], [@bib32], [@bib66], [@bib80], [@bib93]).Figure 3Cryo-EM Structures of the SARS-CoV-2 S Glycoprotein(A) Closed SARS-CoV-2 S trimer unsharpened cryo-EM map.(B and C) Two orthogonal views from the side (B) and top (C) of the atomic model of the closed SARS-CoV-2 S trimer.(D) Partially open SARS-CoV-2 S trimer unsharpened cryo-EM map (one S^B^ domain is open).(E-F) Two orthogonal views from the side (E) and top (F) of the atomic model of the closed SARS-CoV-2 S trimer. The glycans were omitted for clarity. See also [Figures S1](#figs1){ref-type="fig"} and [S2](#figs2){ref-type="fig"}.Figure S1Cryo-EM Data Processing and Validation, Related to [Figures 3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, and [5](#fig5){ref-type="fig"}A-B. Representative electron micrograph (A) and class averages (B) of SARS-CoV-2 S embedded in vitreous ice. Scale bar: 100nm. C. Gold-standard Fourier shell correlation curves for the closed (blue) and partially open trimers (red). The 0.143 cutoff is indicated by horizontal dashed lines. D-E. Local resolution map calculated using cryoSPARC for the closed (D) and partially open (E) reconstructions.Figure S2Comparison of the SARS-CoV-2 and SARS-CoV S Structures, Related to [Figures 3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, and [5](#fig5){ref-type="fig"}Ribbon diagrams of the SARS-CoV-2 S (A) and SARS-CoV S (PDB [6NB6](pdb:6NB6){#intref0100}, D) ectodomain cryoEM structures. The SARS-CoV-2 (B) and SARS-CoV (E) S~1~ subunits. The SARS-CoV-2 (C) and SARS-CoV (F) S~2~ subunits.

As is the case for other β-coronavirus S glycoproteins, including SARS-CoV S ([@bib22], [@bib32], [@bib55], [@bib57], [@bib66], [@bib73], [@bib76], [@bib77], [@bib80], [@bib93]), the S~1~ subunit has a V-shaped architecture ([Figures S2](#figs2){ref-type="fig"}B--S2E). In the closed S trimer, the three hACE2-recognition motifs, whose location was inferred based on the crystal structure of SARS-CoV S^B^ in complex with hACE2 ([@bib39]), are buried at the interface between protomers. As a result, SARS-CoV-2 S^B^ opening is expected to be necessary for interacting with ACE2 at the host cell surface and initiating the conformational changes leading to cleavage of the S~2~′ site, membrane fusion and viral entry ([@bib22], [@bib32], [@bib51], [@bib55], [@bib56], [@bib66], [@bib80], [@bib93]).

As the SARS-CoV-2 and SARS-CoV S~2~ subunits share 88% sequence identity, they are structurally conserved and can be superimposed with 1.2 Å root-mean-square deviation (rmsd) over 417 aligned Cα positions ([Figures S2](#figs2){ref-type="fig"}E and S2F). Only the most N-terminal part of the fusion peptide is resolved in the map, as was the case for previously determined SARS-CoV S structures. The sequence and conformational conservation of the fusion peptide region observed across SARS-CoV-2 S and SARS-CoV S suggests that Abs targeting this functionally important motif might cross-react and neutralize the two viruses as well as related coronaviruses.

We previously showed that coronavirus S glycoproteins are densely decorated by heterogeneous N-linked glycans protruding from the trimer surface ([@bib77], [@bib80], [@bib89]). These oligosaccharides participate in S folding ([@bib63]), affect priming by host proteases ([@bib92]), and might modulate antibody recognition ([@bib55], [@bib80]). SARS-CoV-2 S comprise 22 N-linked glycosylation sequons per protomer and oligosaccharides are resolved in the cryo-EM map for 16 of these sites ([Figure 4](#fig4){ref-type="fig"} ). By comparison, SARS-CoV S possesses 23 N-linked glycosylation sequons per protomer, and we previously experimentally confirmed that at least 19 of them are glycosylated ([@bib80]). 20 out of 22 SARS-CoV-2 S N-linked glycosylation sequons are conserved in SARS-CoV S ([Table 2](#tbl2){ref-type="table"} ). Specifically, 9 out of 13 glycans in the S~1~ subunit and all 9 glycans in the S~2~ subunit are conserved among SARS-CoV-2 S and SARS-CoV S. Furthermore, S~2~ N-linked glycosylation sequons are mostly conserved across SARSr-CoV S glycoproteins, suggesting that accessibility of the fusion machinery to Abs will be comparable among these viruses ([Table 2](#tbl2){ref-type="table"} and [Data S1](#mmc2){ref-type="supplementary-material"}).Figure 4Organization of the SARS-CoV-2 S N-Linked Glycans(A--C) Ribbon diagrams of the SARS-CoV-2 S closed structure rendered as a surface with glycans resolved in the cryo-EM map rendered as dark blue spheres. See also [Table 2](#tbl2){ref-type="table"} and [Data S1](#mmc2){ref-type="supplementary-material"}.Table 2Conservation of N-Linked Glycosylation Sequons in SARS-CoV-2 S and SARS-CoV SSARS-CoV-2 SSARS-CoV SN~17~LT*T*~*21*~*FDP*~*25*~*PA*N~29~YT[N]{.ul}~[61]{.ul}~[VT]{.ul}N~65~VT*H*~*69*~*VS*N~73~HTN~74~GT. . .*S*~*112*~*KT*N~109~KS*N*~*121*~*NA*N~118~NS[N]{.ul}~[122]{.ul}~[AT]{.ul}N~119~STN~149~KS*T*~*146*~*QT*[N]{.ul}~[165]{.ul}~[CT]{.ul}N~158~CT[N]{.ul}~[234]{.ul}~[IT]{.ul}N~227~IT[N]{.ul}~[282]{.ul}~[GT]{.ul}N~269~GT[N]{.ul}~[331]{.ul}~[IT]{.ul}N~318~IT[N]{.ul}~[343]{.ul}~[AT]{.ul}N~330~AT*N*~*370*~*SA*N~357~ST[N]{.ul}~[603]{.ul}~[TS]{.ul}N~589~AS[N]{.ul}~[616]{.ul}~[CT]{.ul}N~602~CT[N]{.ul}~[657]{.ul}~[NS]{.ul}*D*~*643*~*TS*[N]{.ul}~[709]{.ul}~[NS]{.ul}N~691~NT[N]{.ul}~[717]{.ul}~[FT]{.ul}N~699~FS[N]{.ul}~[801]{.ul}~[FS]{.ul}N~783~FS[N]{.ul}~[1074]{.ul}~[FT]{.ul}N~1056~FT[N]{.ul}~[1098]{.ul}~[GT]{.ul}N~1080~GT[N]{.ul}~[1134]{.ul}~[NT]{.ul}N~1116~NTN~1158~HTN~1140~HTN~1173~ASN~1155~ASN~1194~ESN~1176~ES[^4]

SARS-CoV S Elicits Neutralizing Abs Against SARS-CoV-2 S {#sec2.4}
--------------------------------------------------------

Mapping of the sequence conservation across multiple S sequences from the sarbecovirus subgenus underscores that the S~2~ fusion machinery is more conserved than the S~1~ subunit with the highest divergence found within S^A^ and S^B^ ([Figures 5](#fig5){ref-type="fig"}A and 5B). These observations are in line with (1) the fact that some, but not all, of these viruses use ACE2 as entry receptor ([@bib17], [@bib60], [@bib91]); and (2) that the S~1~ subunit is more exposed at the viral surface than the fusion machinery and is likely to be subject to a more stringent selection pressure from the immune system.Figure 5SARS-CoV S Elicits Antibodies Neutralizing SARS-CoV-2 S-Mediated Entry into Host Cells(A and B) Sequence conservation of sarbecovirus S glycoproteins plotted on the SARS-CoV-2 S structure viewed from the side (A) and top (B). The sequence alignment was generated using 48 SARS-CoV-2 S sequences obtained from GISAID in addition to the sequences listed in [Data S1](#mmc2){ref-type="supplementary-material"}.(C) Entry of SARS-CoV-2 S-MLV and SARS-CoV S-MLV is potently inhibited by four SARS-CoV S mouse polyclonal immune plasma.

Based on these observations, we hypothesized that exposure to one of the two viruses could elicit cross-reactive and potentially neutralizing Abs against the other virus. We therefore investigated the ability of plasma from four mice immunized with a stabilized SARS-CoV S to inhibit SARS-CoV-2 S- and SARS-CoV S-mediated entry into target cells. All sera tested completely inhibited transduction of SARS-CoV S-MLV and reduced SARS-CoV-2 S-MLV transduction to ∼10% of control in VeroE6 cells ([Figure 5](#fig5){ref-type="fig"}C). The elicitation of a heterotypic response blocking SARS-CoV-2 S-mediated entry into host cells concurs with the sequence and structural conservation of SARS-CoV-2 S and SARS-CoV S along with their comparable glycans shields and suggests that immunity against one virus of the sarbecovirus subgenus can potentially provide protection against related viruses.

Discussion {#sec3}
==========

Receptor recognition is the first step of viral infection and is a key determinant of host cell and tissue tropism. Enhanced binding affinity between SARS-CoV S and hACE2 was proposed to correlate with increased virus transmissibility and disease severity in humans ([@bib41]). Indeed, SARS-CoV isolates from the three phases of the 2002--2003 epidemic were more efficiently transmitted among humans and more pathogenic than the isolates associated with the 2003--2004 re-emergence that caused only a few cases, in line with their binding affinities for hACE2 ([@bib11], [@bib30], [@bib41]). Moreover, the ability to engage ACE2 from different animal species appears to reflect host susceptibility to SARS-CoV infection and facilitated the jump of the virus from animals to humans ([@bib36], [@bib38]). We report here that SARS-CoV-2 uses hACE2 as an entry receptor and recognizes it with a similar affinity to the 2002--2003 SARS-CoV isolates, which suggests it can spread efficiently in humans, in agreement with the numerous SARS-CoV-2 human-to-human transmission events reported to date.

Besides binding to host cell receptors, priming of the S glycoprotein by host proteases through cleavage at the S~1~/S~2~ and the S~2~′ sites is another crucial factor modulating tropism and pathogenicity ([@bib52]). For instance, entry of the MERS-CoV-related bat coronavirus HKU4 into human cells required addition of exogenous trypsin, indicating that S proteolytic activation of this bat virus did not occur in human cells (despite its ability to recognize human DPP4) ([@bib83], [@bib90]). Subsequent work suggested that a glycan present near the S~1~/S~2~ boundary accounted for the lack of proteolytic priming of HKU4 S and that its removal enhanced pseudovirus entry in human cells ([@bib92]). The presence of a polybasic cleavage site, that can be processed by furin-like proteases, is a signature of several highly pathogenic avian influenza viruses and pathogenic Newcastle disease virus ([@bib33], [@bib67]). Strikingly, SARS-CoV-2 S harbors a furin cleavage site at the S~1~/S~2~ boundary, which is processed during biosynthesis. The presence of a furin cleavage site sets SARS-CoV-2 S apart from SARS-CoV S (and SARSr-CoV S) that possesses a monobasic S~1~/S~2~ cleavage site processed upon entry of target cells ([@bib5], [@bib7], [@bib18], [@bib47], [@bib52], [@bib65]). We speculate that the almost ubiquitous expression of furin-like proteases could participate in expanding SARS-CoV-2 cell and tissue tropism, relative to SARS-CoV, as well as increasing its transmissibility and/or altering its pathogenicity.

We previously suggested that coronaviruses use conformational masking and glycan shielding to limit recognition by the immune response of infected hosts ([@bib77], [@bib80], [@bib89]). Similarly to SARS-CoV S and MERS-CoV S ([@bib22], [@bib32], [@bib55], [@bib66], [@bib80], [@bib93]), we found that the SARS-CoV-2 S trimer exists in multiple, distinct conformational states resulting from S^B^ opening at the trimer apex. These structural changes are necessary for receptor engagement of these three viruses and lead to initiation of fusogenic conformational changes ([@bib66], [@bib79], [@bib80]). In contrast, only closed S trimers have been detected for the four other human-infecting coronaviruses: HCoV-NL63 ([@bib77]), HCoV-OC43 ([@bib73]), HCoV-HKU1 ([@bib31]), and HCoV-229E ([@bib43]). As HCoV-NL63 and HCoV-229E are known to engage protein receptors through S^B^ ([@bib86], [@bib88]), trimer opening is also expected to occur to expose their RBMs that are otherwise buried at the interface between protomers in the closed S trimers ([@bib43], [@bib77]). Regardless of the nature of the receptor and the location of the receptor-binding domains, removal of the trimeric S~1~ crown is expected to be necessary for all coronaviruses to allow the large-scale S~2~ conformational changes leading to fusion of the viral and host membranes ([@bib79]). Collectively, these data underscore that S glycoprotein trimers found in highly pathogenic human coronaviruses appear to exist in partially opened states, while they remain largely closed in human coronaviruses associated with common colds. Based on the aforementioned data correlating the binding affinity of SARS-CoV for hACE2 with the rate of transmissibility, viral replication in distinct species, and disease severity ([@bib21], [@bib38], [@bib41], [@bib81]), we hypothesize that the most pathogenic coronaviruses will exhibit S glycoprotein trimers spontaneously sampling closed and open conformations, as is the case for SARS-CoV-2, SARS-CoV and MERS-CoV.

The striking structural similarity and sequence conservation among the SARS-CoV-2 S and SARS-CoV S glycoproteins emphasize the close relationship between these two viruses that recognize hACE2 to enter target cells. This resemblance is further strengthened by our finding that SARS-CoV S elicited polyclonal Ab responses, potently neutralizing SARS-CoV-2 S-mediated entry into cells. We surmise most of these Abs target the highly conserved S~2~ subunit (including the fusion peptide region) based on its structural similarity across SARS-CoV-2 and SARS-CoV, the lack of cross-reactivity of several S^B^-directed Abs ([@bib71], [@bib87]), and previous reports showing that sera from SARS-CoV-infected individuals target this region ([@bib95]). We note that most SARS-CoV neutralizing Abs isolated to date target the S^B^ domain and that several of them recognize the RBM and prevent receptor engagement ([@bib29], [@bib61], [@bib62], [@bib74], [@bib80]). As the SARS-CoV-2 and SARS-CoV S^B^ domains share 75% amino acid sequence identity, future work will be necessary to evaluate whether any of these Abs neutralize the newly emerged coronavirus. These findings also indicate that it might be difficult to distinguish exposure to SARS-CoV-2 from other SARSr-CoVs in serological studies using S ectodomain trimers and that specific assays will need to be designed. Our results provide a structural framework to identify conserved and accessible epitopes across S glycoproteins that will support ongoing vaccine design efforts. Finally, elicitation of diverse, polyclonal Ab responses might prove key in light of the diversity of viruses circulating in animal reservoirs and in preventing the possible emergence of viral neutralization escape mutants.

STAR★Methods {#sec4}
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Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**AlexaFluor680-conjugated AffiniPure Goat Anti Human IgGJacksonImmunoCat\# 109-625-098\
Lot\# 139337**Biological Samples**57BL/6J MiceJackson LaboratoryCat\# 000664**Chemicals, Peptides, and Recombinant Proteins**ThrombinEMD MilliporeRef\# 605195 Lot\# 2946006One-GloEXPromegaCat\# E8110293-Free Transfection ReagentMillipore SigmaCat\# 72181Lipofectamine-2000 Transfection ReagentThermoFisherCat\# 11668500AdjuvantSigma-AldrichCat\# S6322**Deposited Data**SARS-CoV-2 S CryoEM mapsThis PaperEMD: 21452, EMD: 21457SARS-CoV-2 S atomic modelsThis PaperPDB: [6VXX](pdb:6VXX){#intref0010}, PDB: [6VYB](pdb:6VYB){#intref0015}**Experimental Models: Cell Lines**Freestyle HEK293ThermoFisherCat\# R79007HEK293T/17 adherent[@bib53]ATCC CRL-11268Vero(C1008)E6 adherentECACC General CollectionCat\# 85020206Baby Hamster Kidney (BHK)ATCCCat\# CCL-10\
Lot\# 70009857**Recombinant DNA**pCMV-SARS-CoV-2 S 2P furin cleavage mutationGenscriptN/ApcD5 - ACE2[@bib59]N/ApcDNA3.1- SARS-CoV-2 S^B^GenscriptN/ApcDNA3.1- SARS-CoV S^B^This paperN/ApcDNA3.1(-) --Full-length wild-type SARS-CoV-2 SGenscriptN/ApcDNA3.1(-) --Full-length wild-type SARS-CoV S[@bib53]N/ApCMV-murine leukemia virus gag-pol[@bib53]N/ApTG-Luciferase[@bib53]N/A**Software and Algorithms**UCSF Chimera[@bib19]<https://www.rbvi.ucsf.edu/chimera/>UCSF ChimeraX[@bib20]<https://www.rbvi.ucsf.edu/chimerax/>Coot[@bib15]<https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/>Relion[@bib64], [@bib99][https://www2.mrc-lmb.cam.ac.uk/relion/index.php?title&equals;Main_Page](https://www2.mrc-lmb.cam.ac.uk/relion/index.php?title=Main_Page){#intref0035}Rosetta[@bib16], [@bib84]<https://www.rosettacommons.org/software>Leginon[@bib69]<http://emg.nysbc.org/redmine/projects/leginon/wiki/Leginon_Homepage>WARP[@bib70]<https://github.com/cramerlab/warp>CryoSPARC[@bib58]<https://cryosparc.com>MolProbity[@bib10]<http://molprobity.biochem.duke.edu/>**Other**Octet RedForteBio, Pall LLC<https://www.fortebio.com/products/label-free-bli-detection/8-channel-octet-systems>Anti-Penta-HIS (HIS1K)ForteBio, Pall LLCPart\# 18-5120\
Lot\# 1910224AHisTALON Superflow cartridgeTakaraCat\# 635683\
Lot\# 1509573AHiTrap Protein A HPGE Life SciencesCat\# 29-0485-76Superose 6 Increase 10/300GE Life SciencesCat\# 29-0915-96\
Lot\# 10226998Lacey Formvar/Carbon 400 mesh, Cu GridsTed PellaProd\# 01885-F\
Lot\# 020218

Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact David Veesler (<dveesler@uw.edu>).

The unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

The number of replicates carried out for each experiment is described in the figure/table legends.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Cell lines {#sec4.3.1}

HEK293F is a female human embryonic kidney cell line transformed and adapted to grow in suspension (Life Technologies). HEK293F cells were grown in 293FreeStyle expression medium (Life Technologies), cultured at 37°C with 8% CO~2~ and 130 rpm. HEK293T/17 is a female human embryonic kidney cell line (ATCC). VeroE6 is a female kidney epithelial cell from African green monkey. BHK is a kidney cell line from baby hamsters. All adherent cells were cultured at 37°C with 8% CO2 in flasks with DMEM + 10% FBS + 1% penicillin-streptomycin. Cells lines were not tested for mycoplasma contamination nor authenticated.

Method Details {#sec4.4}
--------------

### Transient expression of SARS-CoV-2 and SARS-CoV S^B^ {#sec4.4.1}

The SARS-CoV S^B^ construct was cloned from a SARS-CoV S ectodomain ([@bib80]) synthesized by GeneArt (ThermoFisher Scientific) into a modified pOPING vector with an N-terminal mu-phosphatase signal peptide and a C-terminal hexa-histidine tag (G-HHHHHH). The boundaries of the construct are N-terminal ~306~RVVPSG~311~ and C-terminal ~571~LDISP~5975~. The SARS-CoV-2 S^B^ construct was synthesized by GenScript into pcDNA3.1- with an N-terminal mu-phosphatase signal peptide and a C-terminal hexa-histidine tag (G-HHHHHH). The boundaries of the construct are N-terminal ~328~RFPN~331~ and C-terminal ~530~STNL~533~. Both constructs were produced in 500mL HEK293F cells grown in suspension using FreeStyle 293 expression medium (Life technologies) at 37°C in a humidified 8% CO~2~ incubator rotating at 130 rpm. The cultures were transfected using 293-Free transfection reagent (Millipore) with cells grown to a density of 1 million cells per mL and cultivated for 3--4 days. The supernatants were harvested and cells resuspended for another 3--4 days, yielding two harvests. Proteins were purified from clarified supernatants using a 5mL Cobalt affinity column (Takara), concentrated and flash frozen in a buffer containing 20 mM Tris pH 8.0 and 300 mM NaCl prior to analysis. SDS-PAGE was run to check purity.

### Transient expression of hACE2 {#sec4.4.2}

Expression and purification of human angiotensin-converting enzyme ectodomain (ACE2, residues 1--614) fused to the Fc region of human IgG (hFc) was performed as previously described ([@bib80]) and cleavage of the Fc fragment was carried out with thrombin. Briefly, hACE2 was produced in 500mL HEK293F cells grown in suspension using FreeStyle 293 expression medium (Life technologies) at 37°C in a humidified 8% CO~2~ incubator rotating at 130 rpm. The cultures were transfected using 293-Free transfection reagent (Millipore) with cells grown to a density of 1 million cells per mL and cultivated for 4 days. The supernatants were harvested and cells resuspended for another four days, yielding two harvests. Clarified supernatants were concentrated using Vivaflow tangential filtration cassettes (Sartorius, 10-kDa cut-off) before affinity purification using a Protein A column (GE LifeSciences) followed by gel filtration chromatography using a Superdex 200 10/300 GL column (GE Life Sciences) equilibrated in 20 mM Tris-HCl, pH 8.0, 100 mM NaCl. The Fc tag was removed by thrombin cleavage in a reaction mixture containing 3 mg of recombinant ACE2-FC ectodomain and 10 μg of thrombin in 20 mMTris-HCl pH8.0, 150 mM NaCl and 2.5 mM CaCl~2~.The reaction mixture was incubated at 25°C overnight and re-loaded in a Protein A column to remove uncleaved protein and the Fc tag. The cleaved protein was further purified by gel filtration using a Superdex 200 column 10/300 GL (GE Life Sciences) equilibrated in a buffer containing 20 mM Tris pH 8.0 and 100 mM NaCl. The purified protein was quantified using absorption at 280 nm and concentrated to approximately 1 mg/mL·

### Pseudovirus production {#sec4.4.3}

MLV-based SARS-CoV S, SARS-CoV-2 S, and SARS-CoV-2 S~fur/mut~ pseudotypes were prepared as previously described ([@bib53]). HEK293T cells were co-transfected using Lipofectamine 2000 (Life Technologies) with an S encoding-plasmid, an MLV Gag-Pol packaging construct and the MLV transfer vector encoding a luciferase reporter, according to the manufacturer's instructions. Cells were incubated for 5 h at 37°C with transfection medium. Cells were then washed with DMEM two times and then DMEM containing 10% FBS was added for 60 h. The supernatants were then harvested and filtered through 0.45-mm membranes, concentrated with a 30kDa membrane for 10 min at 3,000 rpm and then frozen at −80°C.

### Western Blotting {#sec4.4.4}

SARS-CoV S, SARS-CoV-2 S, and SARS-CoV-2 S~fur/mut~ pseudovirions were thawed and 4X SDS loading buffer was added prior to boiling for 10 min at 95°C. Samples were run on a 4%--20% gradient Tris-Glycine Gel (BioRad) and transferred to a PVDF membrane. An anti-S~2~ SARS-CoV S monoclonal primary antibody (1:150 dilution) and an Alexa Fluor 680-conjugated goat anti-human or mouse secondary antibody (1:30,000 and 1:15,000 dilution respectively, Jackson Laboratory) were used for Western-blotting. A LI-COR processor was used to develop images.

### Pseudovirus entry assays {#sec4.4.5}

VeroE6 and BHK cells were cultured in 10% FBS, 1% PenStrep DMEM. BHK or VeroE6 cells were plated into 12 well plates at a density of 0.3 × 10^6^ for 16 h. BHK cells were either not transfected or transfected with 0.8 μg ACE2 per well using standard lipofectamine2000 (Life Technologies) protocols and incubated for another 16 h. 20uL of concentrated pseudovirus was added to the wells after washing three times with DMEM. After 2-3 h, 20% FBS and 2% PenStrep containing DMEM was added to the cells for 48 h. Following the 48-h infection, One-Glo-EX (Promega) was added to the cells in equivalent culturing volume and incubated in the dark for 10 min prior to reading on a Varioskan LUX plate reader (ThermoFisher). For entry inhibition assays, 1:100 diluted plasma was incubated with an equal amount of pseudovirus for 30 min at room temperature prior to infection with normalized amounts of pseudovirus added to the cells. Measurements were done in triplicate and relative luciferase units (RLU) were plotted.

### Biolayer interferometry {#sec4.4.6}

Assays were performed on an Octet Red (ForteBio) instrument at 30°C with shaking at 1,000 RPM. Anti-penta His biosensors were hydrated in water for 30 min prior to a 1 min incubation in 10X kinetics buffer (undiluted). Either SARS-CoV-2 S^B^ or SARS-CoV S^B^ were loaded at 10-20 μg/mL in 10X Kinetics Buffer for 200-900 s prior to baseline equilibration for 180 s in 10X kinetics buffer. Association of ACE2 in 10X kinetics buffer at various concentrations in a two-fold dilution series from 20nM to 2.5nM was carried out for 1,000 s prior to dissociation for 1,000 s. The data were baseline subtracted prior to fitting performed using a 1:1 binding model and the ForteBio data analysis software. Mean k~on~, k~off~ values were determined with a global fit applied to all data. The experiments were done with two separate purification batches of SARS-CoV S^B^, SARS-CoV-2-S^B^, and ACE2 each in duplicate and the average is reported.

### Protein expression and purification {#sec4.4.7}

The SARS-CoV-2 2P S (GenBank: [YP_009724390.1](ncbi-p:YP_009724390.1){#intref0075}) ectodomain was produced in 500mL HEK293F cells grown in suspension using FreeStyle 293 expression medium (Life technologies) at 37°C in a humidified 8% CO2 incubator rotating at 130 rpm The culture was transfected using 293fectin (ThermoFisher Scientific) with cells grown to a density of 1 million cells per mL and cultivated for three days. The supernatant was harvested and cells resuspended for another three days, yielding two harvests. Clarified supernatants were purified using a 5mL Cobalt affinity column (Takara). Purified protein was filtered or concentrated and flash frozen in a buffer containing 20 mM Tris pH 8.0 and 150 mM NaCl prior to cryoEM analysis.

### CryoEM sample preparation and data collection {#sec4.4.8}

3 μL of 0.16 mg/mL SARS-CoV-2 S was loaded onto a freshly glow discharged (30 s at 20 mA) lacey carbon grid with a thin layer of evaporated continuous carbon prior to plunge freezing using a vitrobot MarkIV (ThermoFisher Scientific) using a blot force of −1 and 2.5 s blot time at 100% humidity and 25°C. Data were acquired using the Leginon software ([@bib69]) to control an FEI Titan Krios transmission electron microscope operated at 300 kV and equipped with a Gatan K2 Summit direct detector and Gatan Quantum GIF energy filter, operated in zero-loss mode with a slit width of 20 eV. Automated data collection was carried out using Leginon at a nominal magnification of 130,000x with a pixel size of 0.525 Å. The dose rate was adjusted to 8 counts/pixel/s, and each movie was acquired in super-resolution mode fractionated in 50 frames of 200 ms. 4,500 micrographs were collected in a single session with a defocus range comprised between 1.0 and 2.5 μm.

### Cryo-EM data processing {#sec4.4.9}

Movie frame alignment, estimation of the microscope contrast-transfer function parameters, particle picking and extraction were carried out using Warp ([@bib70]). Particle images were extracted with a box size of 800 binned to 400 yielding a pixel size of 1.05 Å. For each dataset two rounds of reference-free 2D classification were performed using cryoSPARC ([@bib58]) to select well-defined particle images. Subsequently, two rounds of 3D classification with 50 iterations each (angular sampling 7.5° for 25 iterations and 1.8° with local search for 25 iterations) were carried out using Relion ([@bib98]) without imposing symmetry to separate distinct SARS-CoV-2 S conformations. 3D refinements were carried out using non-uniform refinement along with per-particle defocus refinement in cryoSPARC ([@bib58]) using an *ab initio* model generated using cryoSPARC. Particle images were subjected to Bayesian polishing ([@bib99]) before performing another round of non-uniform refinement in cryoSPARC ([@bib58]) followed by per-particle defocus refinement and again non-uniform refinement. Local resolution estimation, filtering and sharpening was carried out using CryoSPARC. Reported resolutions are based on the gold-standard Fourier shell correlation (FSC) of 0.143 criterion and Fourier shell correlation curves were corrected for the effects of soft masking by high-resolution noise substitution ([@bib64]).

### CryoEM model building and analysis {#sec4.4.10}

UCSF Chimera ([@bib19]) and Coot were used to fit atomic models (PDB [6NB6](pdb:6NB6){#intref0080}) into the cryoEM map. The model was subsequently manually rebuilt using Coot and the C3-symmetrized map ([@bib8], [@bib15]). This model was then used to build features specific of the C1-map. N-linked glycans were hand-built into the density where visible and the models were refined and relaxed using Rosetta ([@bib84]). Glycan refinement relied on a dedicated Rosetta protocol, which uses physically realistic geometries based on prior knowledge of saccharide chemical properties ([@bib16]), and was aided by using both sharpened and unsharpened maps. Models were analyzed using MolProbity ([@bib10]), EMringer ([@bib4]), Phenix ([@bib44]) and privateer ([@bib1]) to validate the stereochemistry of both the protein and glycan components ([Table S1](#mmc1){ref-type="supplementary-material"}). Figures were generated using UCSF ChimeraX ([@bib20]) and consurf ([@bib3]).

### Immunizations with SARS-CoV S {#sec4.4.11}

57BL/6J mice were obtained from the Jackson Laboratory and maintained at the Comparative Medicine Facility at the Fred Hutchinson Cancer Research Center. After collecting a pre-bleed, mice were immunized with 5μg of SARS-CoV 2P S ectodomain trimer (this construct was previously described ([@bib80])) formulated in 50μl of PBS and 50μl of Sigma Adjuvant System subcutaneously in the base of the tail at weeks 0, 4, and 12 and bleeds were collected 2 weeks after each immunization. Plasma from immunized animals was heat inactivated at 56°C for 1 h and then stored at 4°C until use. All experiments were conducted at the Fred Hutchinson Cancer Research Center according to approved Institutional Animal Care and Use Committee protocols.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Western-blots and biolayer interferometry assays were performed multiple times with at least two independent preparations of each sample.

No methods were used to determine whether the data met assumptions of the statistical approach.

Data and Code Availability {#sec4.6}
--------------------------

The cryoEM maps and atomic models have been deposited at the Electron Microscopy Data Bank and the Protein Data Bank with accession codes EMD: 21452 and PDB: [6VXX](pdb:6VXX){#intref0085} (closed SARS-CoV-2 S), as well as EMD: 21457 and PDB: [6VYB](pdb:6VYB){#intref0090} (SARS-CoV-2 S with one S^B^ open). A list of software used in this study can be found in the Key Resources Table.

Supplemental Information {#app2}
========================

Table S1. Cryo-EM Data Collection and Refinement Statistics, Related to Figures 3, 4, and 5 Data S1. Amino Acid Sequence Alignment of Sarbecovirus S Glycoproteins, Related to Figures 1, 2, and 5The following sequences were used: SARS-CoV-2 (YP_009724390.1), SARSr-CoV RaTG13 (QHR63300.2), SARS-CoV Urbani (AAP13441.1), SARS-CoV CUHK-W1 (AAP13567.1), SARS-CoV GZ02 (AAS00003.1), SARS-CoV A031 (AAV97988.1), SARS-CoV A022 (AAV91631.1), WIV-16 (ALK02457.1), WIV-1 (AGZ48828.1), SARSr-CoV ZXC21 (AVP78042.1), SARSr-CoV ZC45 (AVP78031.1), SARSr-CoV Rp3 (Q3I5J5.1), SARSr-CoV Rs672 (ACU31032.1).
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